Literature DB >> 6247654

Defect of receptor-cyclase coupling protein in psudohypoparathyroidism.

Z Farfel, A S Brickman, H R Kaslow, V M Brothers, H R Bourne.   

Abstract

Hormone-sensitive adenylate cyclase contains a recently discovered protein component that is required for stimulation of cyclic AMP synthesis by hormones and guanine nucleotides; the component presumably couples the membrane receptor to the cyclase. We studied this protein (termed "N") in erythrocyte membranes of patients with pseudohypoparathyroidism, using assays of the protein's biochemical activity and of its susceptibility to radiolabeling in the presence of [32P]NAD and cholera toxin. By both assays, the protein's activity was reduced by 40 to 50 per cent in erythrocytes of five of 10 patients with Type I pseudohypoparathyroidism as compared with those of normal and hypoparathyroid subjects and one patient with Type II pseudohypoparathyroidism. If activity of the N protein is reduced in other tissues, this deficiency could cause the resistance of target organs in pseudohypoparathyroidism to parathyroid hormone and other hormones that work via cyclic AMP. Erythrocytes of five patients with Type I pseudohypoparathyroidism, all in one family, showed no defect in activity of the N protein; the biochemical defect of this family remains undefined.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6247654     DOI: 10.1056/NEJM198007313030501

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  45 in total

1.  Discordance between genetic and epigenetic defects in pseudohypoparathyroidism type 1b revealed by inconsistent loss of maternal imprinting at GNAS1.

Authors:  Suzanne Jan de Beur; Changlin Ding; Emily Germain-Lee; Justin Cho; Alexander Maret; Michael A Levine
Journal:  Am J Hum Genet       Date:  2003-07-11       Impact factor: 11.025

Review 2.  Molecular genetics of mineral metabolic disorders.

Authors:  R V Thakker
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

3.  A 6-hour human parathyroid hormone (1-34) infusion protocol: studies in normal and hypoparathyroid subjects.

Authors:  A McElduff; D Lissner; M Wilkinson; C Cornish; S Posen
Journal:  Calcif Tissue Int       Date:  1987-11       Impact factor: 4.333

4.  Genetic deficiency of the alpha subunit of the guanine nucleotide-binding protein Gs as the molecular basis for Albright hereditary osteodystrophy.

Authors:  M A Levine; T G Ahn; S F Klupt; K D Kaufman; P M Smallwood; H R Bourne; K A Sullivan; C Van Dop
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

Review 5.  Mutations of signal-transducing G proteins in human disease.

Authors:  P Schnabel; M Böhm
Journal:  J Mol Med (Berl)       Date:  1995-05       Impact factor: 4.599

6.  Maintenance of cellular levels of G-proteins: different efficiencies of alpha s and alpha o synthesis in GH3 cells.

Authors:  Y Li; U Mende; C Lewis; E J Neer
Journal:  Biochem J       Date:  1996-09-15       Impact factor: 3.857

7.  Role of stimulatory GTP-binding protein (Gs) in reduced beta-adrenoceptor coupling in the femoral artery of spontaneously hypertensive rats.

Authors:  M Asano; K Masuzawa; T Matsuda
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

Review 8.  Guanine nucleotide-binding regulatory proteins and dual control of adenylate cyclase.

Authors:  A G Gilman
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

9.  Impaired formation of beta-adrenergic receptor-nucleotide regulatory protein complexes in pseudohypoparathyroidism.

Authors:  J A Heinsimer; A O Davies; R W Downs; M A Levine; A M Spiegel; M K Drezner; A De Lean; K A Wreggett; M G Caron; R J Lefkowitz
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

10.  Deficient adenylate cyclase regulatory protein in renal membranes from a patient with pseudohypoparathyroidism.

Authors:  R W Downs; M A Levine; M K Drezner; W M Burch; A M Spiegel
Journal:  J Clin Invest       Date:  1983-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.